The written notice said Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
To evaluate the safety and effectiveness of the DABRA excimer laser system for use as an atherectomy device for the treatment of peripheral vascular stenoses.
In May 2017, DABRA received FDA 510(k) clearance for use in ablating a channel in occlusive peripheral vascular disease (PAD).
"Pharos has added significant value to my dermatology practice by quickly and painlessly treating stubborn conditions: psoriasis, vitiligo, and atopic dermatitis,” said David J. Goldberg, MD.
“Restenosis, or re-narrowing of an artery post-procedure, is a major problem for my patients,” said C.V. Ramana, MD, principal study investigator. “In my experience, DABRA has provided a highly effective treatment, with minimal vascular trauma, which I believe leads to lower rates of restenosis and longer lasting results,” Dr. Ramana practices at NAADI Healthcare in Oklahoma City, OK.
Dr. Kassab, FACC, FSCAI, FACP. FASA, RPVI, FAHA, FSVM, President & CEO of Michigan Outpatient Vascular Institute, Dearborn, Michigan, continued, “The device has an innate tendency to stay intraluminal in all vessels, is versatile as a single debulking device, is easy to use and is cost-effective. In our experience, DABRA has a very low complication rate and we have not seen any angiographic or clinical evidence of distal embolization.”
Catheter’s Liquid Fill with Solid Window Surface Provides Improved Tissue Removal, Contributing to DABRA’s 95 Percent Success Rate Ra Medical Systems, makers of excimer lasers and catheters for cardiovascular and dermatological diseases, today announced that the United States...
Now Treating Patients with Peripheral Artery Disease in the United States Ra Medical Systems, today announced the commercial launch in the United States of the Company’s groundbreaking DABRA™ System for treatment of Peripheral Artery Disease. This follows FDA...
12Page 1 of 2